VAXART INC. - COMMON STOCK
0,4630
11-марта-25 16:45:00
15 мин. задержка
Акции
+0,0030
+0,65%
Сегодняшний диапазон
0,4500 - 0,4750
ISIN
N/A
Источник
NASDAQ
- Котировки
- Графики
Новости
- Статистика
-
06 сен 2023 16:05:00 Источник Nasdaq GlobeNewswire
-
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
03 авг 2023 16:01:00 Источник Nasdaq GlobeNewswire
-
Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3
27 июл 2023 08:00:01 Источник Nasdaq GlobeNewswire
-
06 июл 2023 08:00:01 Источник Nasdaq GlobeNewswire
-
Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement
26 июн 2023 16:45:00 Источник Nasdaq GlobeNewswire
-
21 июн 2023 16:30:00 Источник Nasdaq GlobeNewswire
-
Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock
07 июн 2023 09:16:01 Источник Nasdaq GlobeNewswire
-
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
06 июн 2023 16:01:27 Источник Nasdaq GlobeNewswire
-
06 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire
-
Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET
31 май 2023 08:00:00 Источник Nasdaq GlobeNewswire
-
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
04 май 2023 16:01:00 Источник Nasdaq GlobeNewswire
-
Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4
28 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire
-
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6
29 мар 2023 08:00:01 Источник Nasdaq GlobeNewswire
-
17 мар 2023 08:00:00 Источник Nasdaq GlobeNewswire
-
Vaxart Provides Business Update and Full Year 2022 Financial Results
15 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire
-
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
08 мар 2023 16:05:14 Источник Nasdaq GlobeNewswire
-
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate
14 фев 2023 08:00:01 Источник Nasdaq GlobeNewswire
-
Vaxart Names Phillip Lee as Chief Financial Officer
19 дек 2022 08:00:00 Источник Nasdaq GlobeNewswire
-
01 дек 2022 08:00:01 Источник Nasdaq GlobeNewswire
-
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
22 ноя 2022 08:30:00 Источник Nasdaq GlobeNewswire